Drugs · acquisition-cost intelligence
Diltiazem Hydrochloride Extended-Release
diltiazem hydrochloride· ingredient diltiazemBenzothiazepine derivatives· DILTIAZEM HYDROCHLORIDE 120 mg/1; DILTIAZEM HYDROCHLORIDE 60 mg/1; DILTIAZEM HYDROCHLORIDE 90 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.70
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other diltiazem products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Diltiazem Hydrochloride | $0.06030 | −$1.64 |
| Cardizem | $0.06893 | −$1.63 |
| Cartia XT | $0.18571 | −$1.52 |
| Cardizem CD | $0.18999 | −$1.51 |
| Diltiazem Hydrochloride Extended-Release | $0.36815 | −$1.33 |
| Cardizem LA | $1.57 | −$0.13030 |
| Matzim LA | $1.77 | +$0.07200 |
Medicare Part D coverage · CY2026
On 290 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.